戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Henoch Schonlein Purpura (HSP) is the commonest systemic
2                                              Henoch-Schonlein purpura (HSP) is the most common type o
3                                     Although Henoch-Schonlein purpura (HSP) can occur at any age from
4 ssive diseases: MEFV in Behcet's disease and Henoch-Schonlein purpura, and A1AT in Wegener's granulom
5 he aetiopathogenesis of Kawasaki disease and Henoch-Schonlein purpura.
6 of childhood, including Kawasaki disease and Henoch-Schonlein purpura.
7                          IgA nephropathy and Henoch-Schonlein purpura nephritis are common glomerular
8 e in the pathogenesis of IgA nephropathy and Henoch-Schonlein purpura nephritis has evolved over the
9                Childhood IgA nephropathy and Henoch-Schonlein purpura nephritis have the potential fo
10 sive agents in pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis, recent data indicate
11 ition is the hallmark of IgA nephropathy and Henoch-Schonlein purpura, the onset of which often follo
12                                    Childhood Henoch-Schonlein purpura is more frequent in the West Mi
13 f the most common vasculitides of childhood: Henoch-Schonlein purpura.
14 tions and molecular changes occurring during Henoch-Schonlein purpura, including cytokines, and endot
15 outcomes of patients with renal disease from Henoch-Schonlein purpura will be summarized.
16  and existing literature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revise
17 ntaneous urticaria, bullous pemphigoid, IgA (Henoch-Schonlein purpura) and IgM/IgG immune complex vas
18 hers have described several polymorphisms in Henoch-Schonlein purpura and Kawasaki Disease as well as
19 llustrations of the various complications of Henoch-Schonlein purpura will be reviewed.
20  information about long-term consequences of Henoch-Schonlein purpura.
21 g predisposing factors in the development of Henoch-Schonlein purpura.
22 f nephritis, or alter the natural history of Henoch-Schonlein purpura.
23            The estimated annual incidence of Henoch-Schonlein purpura was 20.4 per 100000, and was hi
24 l be able to elucidate the manifestations of Henoch-Schonlein purpura, determine appropriate treatmen
25 e genetic susceptibility and pathogenesis of Henoch-Schonlein purpura, but there are still significan
26 netic susceptibility and the pathogenesis of Henoch-Schonlein purpura.
27                                   Studies of Henoch-Schonlein purpura have focused on pathogenesis an
28                           Besides studies of Henoch-Schonlein purpura, advances in pediatric vasculit
29 n concerning the most effective treatment of Henoch-Schonlein purpura has begun to emerge.
30 usceptibility, pathogenesis and treatment of Henoch-Schonlein purpura remains incomplete.
31 to determine the most effective treatment of Henoch-Schonlein purpura, particularly for patients with
32 usceptibility, pathogenesis and treatment of Henoch-Schonlein purpura.
33        The frequency and ethnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer va
34                                  Adult-onset Henoch-Schonlein purpura is unusual, but through case st
35 ranoproliferative glomerulonephritis, and/or Henoch Schoenlein purpura.
36  of a man with a 5-year history of relapsing Henoch-Schonlein purpura (HSP) and macroscopic polyarter
37 led series of treatment protocols for severe Henoch-Schonlein purpura nephritis are mentioned.
38 ation, such as IgA nephropathy, Tn syndrome, Henoch-Schonlein purpura, and malignant transformation,
39  most common pediatric vasculitis syndromes, Henoch-Schonlein purpura and Kawasaki disease.
40 ry glomerulonephritis (SGN) in adults, while Henoch-Schonlein purpura nephritis (HSPN) in children.
41 hirty-one consecutive children affected with Henoch-Schonlein syndrome who were from 3.0 to 12.0 year
42 ficant percentage of patients afflicted with Henoch-Schonlein purpura.
43     Main Outcome and Measures: Children with Henoch-Schonlein syndrome underwent a careful, structure
44 r nonblanching skin lesions in children with Henoch-Schonlein syndrome.
45 31, 2015, among 31 consecutive children with Henoch-Schonlein syndrome.
46 hought to occur very rarely in patients with Henoch-Schonlein syndrome.
47 tics of linear skin lesions in patients with Henoch-Schonlein syndrome.